Cerus (CERS) Asset Writedowns and Impairment (2010 - 2023)

Cerus (CERS) reported Asset Writedowns and Impairment of $1.5 million for Q3 2023, up 375.46% sequentially from -$542000.0 in Q4 2022.

Cerus (CERS) Asset Writedowns and Impairment (2010 - 2023) Analysis & Trends

Cerus (CERS) has 7 years of Asset Writedowns and Impairment data on file, last reported at $1.5 million in Q3 2023.

For the quarter ending Q3 2023, Asset Writedowns and Impairment changed N/A year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2023 stood at $951000.0 (changed N/A YoY), and the FY2023 full-year result was $1.7 million, changed N/A from the prior year.
Asset Writedowns and Impairment improved to $1.5 million in Q3 2023, from -$542000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.5 million in Q3 2023 to a low of -$542000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.40 Bn	176.11 Bn	6.27 Bn
2	Stryker	128.93 Bn	126.05 Bn	3.81 Bn
3	Medtronic	108.35 Bn	99.13 Bn	6.41 Bn
4	Boston Scientific	68.71 Bn	67.25 Bn	3.61 Bn
5	Edwards Lifesciences	48.35 Bn	44.68 Bn	1.29 Bn
6	Dexcom	28.37 Bn	27.25 Bn	750.30 Mn
7	GE HealthCare Technologies	28.04 Bn	25.76 Bn	1.98 Bn
8	Smith & Nephew	26.90 Bn	26.33 Bn	-
9	Koninklijke Philips	24.06 Bn	20.93 Bn	2.07 Bn
10	Cerus	602.81 Mn	522.39 Mn	27.89 Mn

Download Data